Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dermapharm Holding SE M&A Activity 2018

Nov 18, 2018

97_rns_2018-11-18_fc71acd0-0556-44b5-a182-6f2d12fbb53d.html

M&A Activity

Open in viewer

Opens in your device viewer

News Details

Ad-hoc | 18 November 2018 16:37

Dermapharm Holding SE: Signing of contract for the acquisition of EUROMED S.A.

Dermapharm Holding SE / Key word(s): Mergers & Acquisitions

Dermapharm Holding SE: Signing of contract for the acquisition of EUROMED S.A.

18-Nov-2018 / 16:37 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Public disclosure of an insider information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 on market abuse, as amended (Market Abuse Regulation – MAR)

Dermapharm Holding SE: Signing of contract for the acquisition of EUROMED S.A.

Grünwald, November 18, 2018 – Dermapharm Holding SE today signed an agreement to acquire the Spanish company EUROMED S.A.. The purchase agreement is still subject to the approval of the antitrust authorities. Dermapharm’s Management Board expects the transaction to be completed at the beginning of 2019. EUROMED S.A. is a leading manufacturer of standardised herbal extracts and natural active ingredients for the pharmaceutical, nutraceutical and cosmetic industries. In 2019, EUROMED S.A. is expected to generate revenues of EUR 70 million and earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 20 million.

Contact

cometis AG

Claudius Krause

Phone: +49 (0)611 – 205855-28

Fax: +49 (0)611 – 205855-66

E-mail: [email protected]

>End of Ad hoc announcement <


18-Nov-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: [email protected]
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart, Tradegate Exchange
End of Announcement DGAP News Service

show this